🔍 Observations
Topline
- Revenue from operations grew 19.1% YoY (₹7,02,846L → ₹8,37,345L), compounding on a large base — scale is not diluting growth velocity.
- Q4FY26 revenue at ₹2,14,289L grew 12.2% YoY (vs ₹1,90,974L Q4FY25) and 3.6% QoQ — sequential momentum intact.
- No segment data provided, but the pace of capacity addition (PPE up ₹1,49,712L YoY) signals the topline engine is being actively fuelled.
Bottomline
- PAT grew 34.1% YoY (₹1,07,588L → ₹1,44,241L) — bottomline growing nearly 1.8x faster than revenue, confirming strong operating leverage.
- Effective tax rate dropped sharply: 23.5% in FY26 vs 23.5% in FY25 headline-level, but FY25 included a deferred tax credit (₹562L) vs FY26 deferred charge (₹2,186L), masking an underlying cash tax improvement.
- Q4FY26 PAT at ₹34,222L grew 7.3% YoY (vs ₹31,900L Q4FY25) — solid, though Q4FY25 had a higher current tax outflow (₹7,213L vs ₹5,858L), flattering the comparison.
Margins
- EBITDA proxy (PBT before exceptional + D&A + Finance costs): FY26 = ₹1,72,382L + ₹44,653L + ₹23,510L = ₹2,40,545L on revenue of ₹8,37,345L → EBITDA margin ~28.7% vs FY25: (₹1,48,000L + ₹35,942L + ₹16,502L) / ₹7,02,846L = ₹2,00,444L → ~28.5% — margins essentially flat despite revenue scale-up.
- Net profit margin: ₹1,44,241L / ₹8,37,345L = 17.2% vs ₹1,07,588L / ₹7,02,846L = 15.3% — 190bps expansion, driven by operating leverage on fixed costs.
- Finance costs surged 42.5% YoY (₹16,502L → ₹23,510L), partially offsetting operating gains; bears watching as debt expands with capex.
Growth Trajectory
- Revenue CAGR implied over FY25–26 at 19.1% on a ₹700Cr+ base is exceptional for a hospital network — pricing power + volume both contributing.
- PAT growing at 34% with EBITDA flat suggests the leverage point is below EBITDA: D&A and finance costs are scaling, but PBT-to-PAT conversion is improving.
- Capacity buildout (CWIP conversion + fresh PPE additions) suggests FY27 will test whether new beds can ramp revenues fast enough to sustain margin trajectory.